Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NICE
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
- NCT03016871 ↗
- Active, not recruiting
- City of Hope Medical Center
- Standard
We haven't built an HCP commentary report on NICE (nivolumab; nivolumab plus ICE in relapsed or refractory Hodgkin lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NICE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
- Interventions
- Carboplatin; Etoposide; Ifosfamide; Laboratory Biomarker Analysis; Nivolumab
- Arms
- Cohort A (nivolumab, etoposide, ifosfamide, carboplatin) · Experimental
- Cohort B (nivolumab, etoposide, ifosfamide, carboplatin) · Experimental
- Enrollment
- 78
- Primary outcomes
- Complete Response Rate by Lugano Classification
- Number of Participants With Unacceptable Adverse Events
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI)
- Start
- Apr 24, 2017
- Primary completion
- Jan 30, 2024
- Results posted
- Yes
- Registry record
- NCT03016871 · updated Aug 25, 2026
Publications
linked from the registry- Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. PubMed 35316328